Sao Paulo's Butantan says vaccination output depends on ingredients from China

The Butantan biomedical center in Sao Paulo needs more active ingredients from China's Sinovac Biotech by the end of the month in order to hit targets for producing finished doses of a COVID-19 vaccine, the head of the institute said on Monday.

Butantan Director Dimas Covas told a news conference that the shipment from Sinovac was still waiting for export approval from the Chinese government.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)